Genor Biopharma (Stock code: 6998.HK) announced today that the first patient has been successfully dosed in a Phase I/II clinical trial of GB263T, a novel EGFR/cMET/cMET trispecific therapeutic antibody, in China for the treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.

With the theme of “Only the innovators can make steady progress”, the press conference of the 2021 Chinese Biopharma Companies Innovation TOP 100 Series Lists was held online on September 16, 2022. Genor Biopharma remained included in the Chinese Antibody Drug Companies Innovation TOP 30.

Genor Biopharma (Stock code: 6998.HK) announced today that the first patient has been successfully dosed in a Phase I/II clinical trial of GB261(CD20/CD3, bispecific antibody) in China.

Genor Biopharma (Stock code: 6998.HK) today announced its interim results for 2022, sharing the company's business progress, financial data, and highlights during the period.

Genor Biopharma (Stock code: 6998.HK) announced today that the company has entered into a cooperative development agreement (the “Cooperative Development Agreement”) with Suzhou Abogen Biosciences Co., Ltd (“Abogen”) to jointly develop globally innovative mRNA products and related pharmaceuticals.